Keytruda is the reason Jimmy Carter is alive today
Post# of 36537
AE37 alone showed remarkable strength against triple negative breast cancer in the last trial (89% disease free with AE37 after 55 months, vs 0% disease free in the control group). N is only 21, but .05 p value, which means it is significant even with the low n of 21.
If this upcoming trial with metastatic triple negative bc shows good results early on, I wonder if approval could be given early. That is happening more and more with cancer immunological drugs. And metastatic TN BC is considered incurable at present, with a mean survival time after relapse of something like 9 months. So the FDA has plenty of incentive to accelerate approval using one of their designations such as "breakthough therapy".